Recent Publications
- Colbert CM, et al Comparison of Three USPIOs for MRI at 3.0T. JMRI 2022
- Yoshida T, et al Ferumoxytol-enhanced 4D multiphase, steady-state imaging with magnetic resonance in congenital heart disease: ventricular volume and function across 2D and 3D software platforms. QIMS 2022
- Gao C, et al. Undersampling artifact reduction for free-breathing 3D stack-of-radial MRI based on a deep adversarial learning network. Magn Reson Imaging 2022
- Shahrouki P, et al High-resolution three‑dimensional contrast‑enhanced magnetic resonance venography in children: comparison of gadofosveset trisodium with ferumoxytol. Pediatr Radiol 2022
- Hazany S, et al. Regional cerebral small vessel disease (rSCVD) score: a clinical MRI grading system validated in a stroke cohort. J Clinical Neurosci 2022.
- Berg CJ, et al. Left atrial mechanics and diastolic function among people living with human immunodeficiency virus (from the Veterans Aging Cohort Study). Am J Card 2022.
- Colbert CM, et al. Fractional myocardial blood volume by ferumoxytol-enhanced MRI: estimation of ischemic burden. Magn Reson Med 2022.
Upcoming Conferences
You can see our work at:
- SCMR 2023, San Diego, CA
- ISMRM 2023, Toronto, Canada
FeraSafe Registry
FeraSafe is a multi-center safety registry designed to promote the safe and appropriate use of ferumoxytol for MR imaging applications. FeraSafe aims to facilitate collaborations among institutions exploring the theranostic use of ferumoxytol. FeraSafe is developed and maintained by UCLA investigators.